MADHAVBAUG

Vaidya Sane Ayurved Laboratories Limited

Listed company · ISIN INE0JR301013 · NSE ST · FV ₹10
Last price
₹178
+2.93%today
What this company does

Vaidya Sane Ayurved Laboratories Limited is a listed company. It booked ₹57 cr of revenue in its latest half year (H2 FY26) and kept 7.3% of sales as profit.

59out of 100
Equitytale Health Score
Mixed

Healthier than 59% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,334–2,885 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
54

At close. Not part of the score.

Profitability & returns48

How much profit it earns on the money it employs

Balance sheet73

How much it owes, and whether earnings cover the interest

Cash quality42

Whether reported profit actually arrives as cash

Valuation46

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
A mixed picture
Strengths
✓ Makes a profit
✓ Promoters hold 66%
✓ No promoter shares pledged
✓ Virtually debt-free
Watch-outs
! Thin 7.3% net margin

What if I invest in MADHAVBAUG?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹178▲ +2.93%
latest close · 2026-10-01
52-wk low ₹98125 sessions so far52-wk high ₹249
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio22.5Average
LowAverageHigh
P/B ratio3.05High
Below bookModerateHigh
EV / EBITDA18.6High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity13.6%Fair
WeakFairStrong ▸15%
Return on capital10.9%Fair
WeakFairStrong
Net margin7.3%Decent
ThinDecentStrong
EBITDA margin8.9%Thin
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.04Comfortable
LowModerateHigh ▸1
Interest cover6.8×Strong
RiskyOkayStrong ▸5×
Current ratio3.99Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹187 cr
Book value
₹58
EPS
₹3.95
latest half year
Net debt
₹2 cr
owes more than its cash
Enterprise value
₹189 cr
EBITDA
₹10 cr
annualised
EBIT
₹10 cr
annualised
Operating margin
8.9%
Return on assets
8.0%
Earnings yield
4.45%
P/S
1.64
Sales / share
₹108.3
Tax rate
4.2%
Face value
₹10
Shares
1.1 cr
Working capital
₹33 cr
Current assets
₹44 cr
Current liabilities
₹11 cr
Delivery %
97.8%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹62–₹62, midpoint ₹62

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹57 cr
Other Income₹1 cr
Total Income₹58 cr
Cost of Materials₹11 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹9 cr
Finance Costs₹74.5 L
Other Expenses₹31 cr
Total Expenses₹54 cr
Profit before Tax₹4 cr
Tax Expense₹18.4 L
Net Profit₹4 cr
Net margin on total income7.1%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹11 cr18.2%
Employee benefit expense₹9 cr14.7%
Finance costs₹74.5 L1.3%
Other expenses₹34 cr58.4%
Tax expense₹18.4 L0.3%
Profit for the period₹4 cr7.1%
Total income ₹58 cradds up to ₹100 ✓
Half-yearly results · consolidated (₹ cr)
MetricH1 FY26H2 FY26
Revenue50 cr57 cr
Total income51 cr58 cr
Expenses44 cr54 cr
Profit before tax6 cr4 cr
Tax2 cr18.4 L
Net profit (owners' share)5 cr4 cr
Net margin (owners' share, on revenue)9.7%7.3%
EPS (₹)4.563.95
Balance sheet & cash flow · as of Mar 2026
Debt-free
Total assets
₹105 cr
Shareholder equity
₹61 cr
parent shareholders
Total debt
₹3 cr
Cash
₹43.7 L
Who owns it · 2026-03-31
No pledge
Promoter
66.3%
Public
33.7%
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 30 Sep 2026
See the official result
1
Resolution 1 : . Adoption of Financial Statements:
Backed by 100% of shareholders other than promotersneeded 50%
71.47 L votes for, 0 against · 0% of mutual funds and other big investors said no
2
Resolution 2 : Appointment of Mrs. Vidyut Bipin Ghag (DIN: 09299252) as director liable to retire by rotation
Backed by 100% of shareholders other than promotersneeded 50%
71.47 L votes for, 0 against · 0% of mutual funds and other big investors said no
3
Resolution 3 : Reappointment of M/s. A.A. Mohare & Co. Chartered Accountants (Firm Registration No. 114152W) statutory auditors of the Company
Backed by 100% of shareholders other than promotersneeded 50%
71.47 L votes for, 0 against · 0% of mutual funds and other big investors said no
4
Resolution 4 : Re-appointment of Mr. Ratnakar Venkappa Rai (DIN: 00126309) as Non-Executive Independent Director of the company for a second term:
Backed by 100% of shareholders other than promotersneeded 75%
71.47 L votes for, 0 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 3 named members
owning 66.3% between them · as of 2026-03-31
ROHIT MADHAV SANE66.29%
REKHA JITESH PARALKAR .0.05%
Medemy Life Sciences Private Limitedno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

Money raised in Jan 2026 by selling shares to selected investors

The company has not broken this money down into purposes in its filing for Mar 2026, so there is nothing to measure it against yet.

The amount this filing states as raised is many times the whole company’s market value, so it is almost certainly entered in the wrong unit. We show the purposes and how far along each one is, and leave the rupee figures out rather than repeat a number that cannot be right.

Money raised in Aug 2023 by selling shares to selected investors

The company has not broken this money down into purposes in its filing for Mar 2026, so there is nothing to measure it against yet.

The amount this filing states as raised is many times the whole company’s market value, so it is almost certainly entered in the wrong unit. We show the purposes and how far along each one is, and leave the rupee figures out rather than repeat a number that cannot be right.

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.